Hims & Hers Health (NYSE:HIMS) Price Target Raised to $27.00

Hims & Hers Health (NYSE:HIMS) had its target price upped by Deutsche Bank Aktiengesellschaft from $23.00 to $27.00 in a research note published on Wednesday morning,Benzinga reports. The firm currently has a hold rating on the stock.

Several other brokerages have also issued reports on HIMS. Imperial Capital lowered Hims & Hers Health from an “outperform” rating to an “in-line” rating in a research report on Friday, August 9th. Needham & Company LLC initiated coverage on Hims & Hers Health in a research report on Thursday, August 22nd. They issued a “buy” rating and a $24.00 price objective for the company. Bank of America lifted their price objective on Hims & Hers Health from $23.00 to $25.00 and gave the stock a “buy” rating in a research report on Monday, October 21st. Truist Financial lifted their price objective on Hims & Hers Health from $13.00 to $23.00 and gave the stock a “hold” rating in a research report on Thursday, July 18th. Finally, Canaccord Genuity Group lifted their price objective on Hims & Hers Health from $24.00 to $28.00 and gave the stock a “buy” rating in a research report on Tuesday. Eight research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. Based on data from MarketBeat, Hims & Hers Health presently has a consensus rating of “Moderate Buy” and a consensus price target of $21.21.

Hims & Hers Health Trading Down 0.9 %

NYSE:HIMS traded down $0.21 on Wednesday, hitting $23.41. The company’s stock had a trading volume of 17,983,781 shares, compared to its average volume of 13,702,758. The firm has a market capitalization of $5.03 billion, a P/E ratio of 53.22 and a beta of 1.06. Hims & Hers Health has a one year low of $6.58 and a one year high of $25.74. The stock has a fifty day moving average of $18.75 and a two-hundred day moving average of $18.41.

Hims & Hers Health (NYSE:HIMS) last announced its earnings results on Monday, November 4th. The company reported $0.32 earnings per share for the quarter, topping analysts’ consensus estimates of $0.06 by $0.26. The company had revenue of $401.56 million for the quarter, compared to analyst estimates of $382.20 million. Hims & Hers Health had a return on equity of 10.97% and a net margin of 8.19%. The firm’s quarterly revenue was up 77.1% compared to the same quarter last year. During the same quarter last year, the company earned ($0.04) earnings per share. As a group, sell-side analysts anticipate that Hims & Hers Health will post 0.22 EPS for the current year.

Insider Activity at Hims & Hers Health

In other Hims & Hers Health news, Director Christiane Pendarvis sold 7,000 shares of Hims & Hers Health stock in a transaction dated Tuesday, August 27th. The stock was sold at an average price of $15.15, for a total transaction of $106,050.00. Following the completion of the transaction, the director now owns 23,917 shares in the company, valued at approximately $362,342.55. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. In other Hims & Hers Health news, Director Christiane Pendarvis sold 7,000 shares of the business’s stock in a transaction that occurred on Tuesday, August 27th. The stock was sold at an average price of $15.15, for a total transaction of $106,050.00. Following the completion of the sale, the director now directly owns 23,917 shares of the company’s stock, valued at approximately $362,342.55. The trade was a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Soleil Boughton sold 2,339 shares of the business’s stock in a transaction that occurred on Tuesday, October 29th. The stock was sold at an average price of $23.16, for a total value of $54,171.24. Following the sale, the insider now directly owns 169,935 shares of the company’s stock, valued at $3,935,694.60. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 854,547 shares of company stock valued at $15,987,230 in the last three months. Corporate insiders own 17.71% of the company’s stock.

Institutional Trading of Hims & Hers Health

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Carnegie Investment Counsel bought a new position in shares of Hims & Hers Health in the third quarter valued at approximately $5,531,000. International Assets Investment Management LLC bought a new position in shares of Hims & Hers Health in the third quarter valued at approximately $6,790,000. Sei Investments Co. grew its holdings in shares of Hims & Hers Health by 206.9% in the first quarter. Sei Investments Co. now owns 56,202 shares of the company’s stock valued at $869,000 after acquiring an additional 37,890 shares in the last quarter. Quantbot Technologies LP grew its holdings in shares of Hims & Hers Health by 3,444.9% in the first quarter. Quantbot Technologies LP now owns 214,677 shares of the company’s stock valued at $3,321,000 after acquiring an additional 208,621 shares in the last quarter. Finally, Healthcare of Ontario Pension Plan Trust Fund grew its holdings in shares of Hims & Hers Health by 164.1% in the second quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 528,142 shares of the company’s stock valued at $10,663,000 after acquiring an additional 328,142 shares in the last quarter. 63.52% of the stock is owned by institutional investors.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.